BioCentury | Apr 1, 2013
Clinical News

OHR/AVR118: Phase II data

...be reached for next steps. In 2009, the company acquired OHR/AVR118 from the now-defunct Advanced Viral Research...
BioCentury | Dec 14, 2009
Clinical News

OHR118: Phase II data

...of Cachexia and Wasting Disorders meeting in Barcelona. Ohr acquired OHR118 from the now-defunct Advanced Viral Research...
BioCentury | Dec 7, 2009
Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

...diabetes. Genaera's board voted to dissolve the biotech in June (see BioCentury, June 22). Advanced Viral Research...
BioCentury | Feb 2, 2009
Company News

Advanced Viral cancer, infectious news

...Advanced Viral had $232,769 in cash and a nine-month operating loss of $2.2 million. Advanced Viral Research...
BioCentury | Mar 3, 2008
Company News

Advanced Viral, Northeastern University deal

...technology. The company will have rights to resulting IP. Financial terms were not disclosed. Advanced Viral Research...
BioCentury | Dec 10, 2007
Company News

Advanced Viral deal

...will join ADVR as CSO and VP of research, respectively. Cetek no longer exists. Advanced Viral Research...
BioCentury | Dec 10, 2007
Company News

Advanced Viral management update

...Advanced Viral Research Corp. (ADVR), Yonkers, N.Y. Business: Cancer, Infectious Hired: Vincent Gullo as CSO, formerly VP...
BioCentury | Oct 8, 2007
Clinical News

AVR118: Phase II started

...this first cohort, up to 30 additional patients could be enrolled in the trial. Advanced Viral Research...
BioCentury | Sep 10, 2007
Clinical News

AVR118: Phase II start

...the results from this first cohort, the trial could enroll at least 32 patients. Advanced Viral Research...
BioCentury | Jun 25, 2007
Clinical News

AVR118: Preliminary Phase II data

...had plastic surgery. The trial is expected to enroll a total of 20 patients. Advanced Viral Research...
Items per page:
1 - 10 of 84
BioCentury | Apr 1, 2013
Clinical News

OHR/AVR118: Phase II data

...be reached for next steps. In 2009, the company acquired OHR/AVR118 from the now-defunct Advanced Viral Research...
BioCentury | Dec 14, 2009
Clinical News

OHR118: Phase II data

...of Cachexia and Wasting Disorders meeting in Barcelona. Ohr acquired OHR118 from the now-defunct Advanced Viral Research...
BioCentury | Dec 7, 2009
Company News

Advanced Viral, Ohr endocrine, dermatology, ophthalmic news

...diabetes. Genaera's board voted to dissolve the biotech in June (see BioCentury, June 22). Advanced Viral Research...
BioCentury | Feb 2, 2009
Company News

Advanced Viral cancer, infectious news

...Advanced Viral had $232,769 in cash and a nine-month operating loss of $2.2 million. Advanced Viral Research...
BioCentury | Mar 3, 2008
Company News

Advanced Viral, Northeastern University deal

...technology. The company will have rights to resulting IP. Financial terms were not disclosed. Advanced Viral Research...
BioCentury | Dec 10, 2007
Company News

Advanced Viral deal

...will join ADVR as CSO and VP of research, respectively. Cetek no longer exists. Advanced Viral Research...
BioCentury | Dec 10, 2007
Company News

Advanced Viral management update

...Advanced Viral Research Corp. (ADVR), Yonkers, N.Y. Business: Cancer, Infectious Hired: Vincent Gullo as CSO, formerly VP...
BioCentury | Oct 8, 2007
Clinical News

AVR118: Phase II started

...this first cohort, up to 30 additional patients could be enrolled in the trial. Advanced Viral Research...
BioCentury | Sep 10, 2007
Clinical News

AVR118: Phase II start

...the results from this first cohort, the trial could enroll at least 32 patients. Advanced Viral Research...
BioCentury | Jun 25, 2007
Clinical News

AVR118: Preliminary Phase II data

...had plastic surgery. The trial is expected to enroll a total of 20 patients. Advanced Viral Research...
Items per page:
1 - 10 of 84